These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17903146)

  • 1. Studies in animal model on the thrombogenicity of a new prothrombin complex concentrate from Argentina.
    Bernardi ME; Vitali MS; Moya C; Guglielmone HA; Cuadra GR
    Transfus Med; 2007 Oct; 17(5):420-2. PubMed ID: 17903146
    [No Abstract]   [Full Text] [Related]  

  • 2. Prothrombin complex concentrate and fatal thrombosis: poor evidence to implicate a relatively safe drug.
    Sarode R; Matevosyan K
    Ann Emerg Med; 2009 Sep; 54(3):481-2; author reply 482-3. PubMed ID: 19695429
    [No Abstract]   [Full Text] [Related]  

  • 3. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
    Kim HC; Matts L; Eisele J; Czachur M; Saidi P
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):15-9. PubMed ID: 1780766
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo modelling of coagulation factor concentrate thrombogenicity.
    MacGregor I; Drummond O; Prowse C
    Thromb Haemost; 1997 Feb; 77(2):405-6. PubMed ID: 9157607
    [No Abstract]   [Full Text] [Related]  

  • 6. Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate.
    Warren O; Simon B
    Ann Emerg Med; 2009 Jun; 53(6):758-61. PubMed ID: 19181420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracardiac Thrombosis after Emergent Prothrombin Complex Concentrate Administration for Warfarin Reversal.
    Goldhammer JE; Bakowitz MJ; Milas BL; Patel PA
    Anesthesiology; 2015 Aug; 123(2):458. PubMed ID: 25264598
    [No Abstract]   [Full Text] [Related]  

  • 8. The dangers of prothrombin complex concentrate administration after heart surgery.
    White R; Rushbrook J; McGoldrick J
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):609-10. PubMed ID: 18685448
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
    Ostermann H; Haertel S; Knaub S; Kalina U; Jung K; Pabinger I
    Thromb Haemost; 2007 Oct; 98(4):790-7. PubMed ID: 17938803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombosis and disseminated intravascular coagulation following treatment with the prothrombin complex concentrate, DEFIX.
    Roddie PH; Stirling C; Mayne EE; Ludlam CA
    Thromb Haemost; 1999 Apr; 81(4):667. PubMed ID: 10235464
    [No Abstract]   [Full Text] [Related]  

  • 11. Myocardial necrosis after therapy with prothrombin-complex concentrate.
    Lusher JM
    N Engl J Med; 1984 Feb; 310(7):464. PubMed ID: 6694689
    [No Abstract]   [Full Text] [Related]  

  • 12. Prothrombin overload causes thromboembolic complications in prothrombin complex concentrates: in vitro and in vivo evidence.
    Grundman C; Plesker R; Kusch M; Hanschmann KM; Eich S; Seitz R; König H
    Thromb Haemost; 2005 Dec; 94(6):1338-9. PubMed ID: 16411418
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of prothrombin complex concentrate in healthy subjects.
    Barco S; Picchi C; Trinchero A; Middeldorp S; Coppens M
    Br J Haematol; 2017 Feb; 176(4):664-666. PubMed ID: 27027385
    [No Abstract]   [Full Text] [Related]  

  • 14. In vivo models of thrombogenic potential: usefulness and limitations.
    MacGregor I; McLaughlin L; Drummond O; Prowse C; Ferguson J
    Acta Haematol; 1995; 94 Suppl 1():18-23; discussion 24. PubMed ID: 7571990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prothrombin complex concentrates: a brief review.
    Samama CM
    Eur J Anaesthesiol; 2008 Oct; 25(10):784-9. PubMed ID: 18538049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate.
    Dickneite G; Doerr B; Kaspereit F
    Anesth Analg; 2008 Apr; 106(4):1070-7, table of contents. PubMed ID: 18349175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complications of therapy in hemophilia.
    Hilgartner MW
    Pediatrics; 1984 Aug; 74(2):290-1. PubMed ID: 6462828
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of massive bleeding with prothrombin complex concentrate: argument against.
    Godier A; Susen S; Samama CM
    J Thromb Haemost; 2010 Dec; 8(12):2592-5. PubMed ID: 20860676
    [No Abstract]   [Full Text] [Related]  

  • 19. [Experimental studies on prevention of thrombosis design of a new experimental model].
    Sumida S; Yagi H; Hamatake Y; Tashiro T
    Nihon Kyobu Geka Gakkai Zasshi; 1974 May; 22(5):445-8. PubMed ID: 4474225
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
    Treur MJ; McCracken F; Heeg B; Joshi AV; Botteman MF; De Charro F; Van Hout B
    Haemophilia; 2009 Mar; 15(2):420-36. PubMed ID: 19335751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.